Sonnet Biotherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, Son-1411 and Son-1400, Each Containing a Variant Il-18 Domain
Sonnet Biotherapeutics宣佈生成並表徵了兩個新的免疫治療藥物候選品-Son-1411和Son-1400，每個都包含一個變異的Il-18結構域。